Efficacy of Sativex® on pain, spasticity, and disability in patients with multiple sclerosis: A systematic review and meta-analysis
Nucera et al.·Pharmacological ResearchImpact 10.0
Clear benefitGRADEHigh0 citations
Samplek = 20 Studien
Durationunclear
ControlPlacebo and/or active comparators
EndpointNRS
Blindingunklar
DesignSystematische Review + Meta-Analyse
Cannabinoidkombination
THC:CBD1:1
Routeoromukosal
”Key finding
Sativex showed significant reduction of pain intensity and spasticity as well as modest but significant improvement in disability in MS patients.
Summary
Systematic review and meta-analysis across k=20 studies on Sativex® (nabiximols) in multiple sclerosis. Significant reduction in pain intensity (NRS, SMC −0,88; 95% CI −1,20 to −0,57; p<0,0001) and spasticity (SMC −1,29; 95% CI −1,63 to −0,94; p<0,0001); modest but significant improvement in disability (EDSS, SMC −0,17; 95% CI −0,28 to −0,07; p=0,0015). Conclusion: Sativex as an effective treatment option against pain and spasticity in MS.
OutcomeSignificant pain reduction (NRS, SMD -0,88, 95% CI -1,20 to -0,57, p<0,0001); significant reduction in spasticity (SMD -1,29, 95% CI -1,63 to -0,94, p<0,0001); moderate improvement in disability (EDSS, SMD -0,17, 95% CI -0,28 to -0,07, p=0,0015)
Confidence in the evidence
Very lowLowModerateHigh
High
The highest of four GRADE levels, the effect estimate is very reliable.
Multiple Sclerosis (MS) is a neurological disorder ... This systematic review and meta-analysis evaluated the efficacy of Sativex (Nabiximols) in pain control, spasticity and disability in MS. A PRISMA literature search of PubMed, Scopus and Web of Science retrieved 1203 articles, of which 20 met the inclusion criteria. Results: significant reduction in pain intensity (NRS, SMC -0.88, 95% CI -1.20 to -0.57, p<0.0001); significant reduction in spasticity (SMC -1.29, 95% CI -1.63 to -0.94, p<0.0001); modest but significant improvement in disability (EDSS, SMC -0.17, 95% CI -0.28 to -0.07, p=0.0015). Source: PubMed PMID 42142680.